Evidence map›Paper›PMID 31796976›Full record

ReviewHerz2021

Cardiac amyloidosis: in search of the ideal diagnostic tool.

Sophie I Mavrogeni, Vasiliki Vartela, Argyrios Ntalianis, Rosa Vretou, Ignatios Ikonomidis, Marini Tselegkidou, Ioannis Paraskevaidis, George Markousis-Mavrogenis, Michel Noutsias, Angelos Rigopoulos and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Herz, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Sophie I MavrogeniOnassis Cardiac Surgery Center, 50 Esperou Street, 175-61, P. Faliro, Athens, Greece. soma13@otenet.gr.
Vasiliki VartelaOnassis Cardiac Surgery Center, 50 Esperou Street, 175-61, P. Faliro, Athens, Greece.
Argyrios NtalianisAlexandra's Hospital, Athens, Greece.
Rosa VretouAttikon Hospital, Athens, Greece.
Ignatios IkonomidisAttikon Hospital, Athens, Greece.
Marini TselegkidouAlexandra's Hospital, Athens, Greece.
Ioannis ParaskevaidisAlexandra's Hospital, Athens, Greece.
George Markousis-MavrogenisOnassis Cardiac Surgery Center, 50 Esperou Street, 175-61, P. Faliro, Athens, Greece.
Michel NoutsiasMid-German Heart Center, Department of Internal Medicine III (KIM-III), Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst-Grube-Straße 40, 06120, Halle (Saale), Germany.
Angelos RigopoulosMid-German Heart Center, Department of Internal Medicine III (KIM-III), Division of Cardiology, Angiology and Intensive Medical Care, University Hospital Halle, Martin-Luther-University Halle, Ernst-Grube-Straße 40, 06120, Halle (Saale), Germany.
Genovefa KolovouOnassis Cardiac Surgery Center, 50 Esperou Street, 175-61, P. Faliro, Athens, Greece.
Efstathios KastritisAlexandra's Hospital, Athens, Greece.
Alexandra Hospital · GROnassis Cardiac Surgery Center · GRMartin Luther University Halle-Wittenberg · DEUniversity General Hospital Attikon · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCardiac amyloidosis (CA) is due to amyloid deposition in the myocardium. Transthyretin (ATTR) and light-chain (AL) amyloidosis are the main types of CA. Here, we present the clinical and imaging findings in patients with CA and discuss the controversies with the aim of finding the ideal diagnostic tool.

methodsTen patients suspected of having CA on the basis of electrocardiographic (ECG) and echocardiographic findings were evaluated via cardiovascular magnetic resonance imaging (CMR; 1.5 T) using cine, late gadolinium enhancement (LGE), T1, T2 mapping, and extracellular volume fraction. N‑terminal pro-B-type natriuretic peptide (NT-proBNP) levels were also assessed in all patients.

resultsAll ten patients had an echocardiogram suggestive of CA. The CMR study documented ventricular hypertrophy leading to small ventricular volumes, as assessed by echocardiography. Diffuse subendocardial LGE, supporting the diagnosis of CA, was identified in all except one patient, who had subepicardial LGE due to myocarditis that was verified by endomyocardial biopsy (EMB). Right ventricular (RV) involvement was identified in four of the ten patients, whose condition deteriorated rapidly over the next 6 months. The NT-proBNP levels were >332 pg/ml in all except two patients. Light-chain amyloidosis was identified via fat tissue biopsy in two patients and through renal biopsy in one patient. In two patients with positive technetium-99m, EMB confirmed the diagnosis of ATTR.

conclusionNT-proBNP may be a sensitive but nonspecific biomarker for assessing CA. However, CMR is the only imaging modality that can assess the pathophysiologic background of cardiac hypertrophy and the severity of CA, irrespective of NT-proBNP level.

Indexed as

AmyloidosisCardiomyopathiesContrast MediaGadoliniumHumansMagnetic Resonance ImagingMyocardiumPredictive Value of TestsPrognosisContrast MediaGadoliniumCardiac amyloidosisCardiovascular magnetic resonance imagingEchocardiographyElectrocardiographyN‑terminal pro-BNP

Identifiers

PMID31796976
OpenAlexW2994532939

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.